leadf
logo-loader
viewModerna Therapeutics Inc

Moderna announces positive interim data on Covid-19 vaccine candidate

The next set of trials, potentially scheduled for July, will be the final stage before submitting the candidate to the authorities

Moderna Therapeutics Inc - Moderna announces positive interim data on Covid-19 vaccine candidate

Moderna Inc (NASDAQ:MRNA) has announced positive interim clinical data of its vaccine candidate against Covid-19.

The US biotech firm said the new data reinforces the belief that its mRNA-based vaccine could be effective in preventing infections, without serious side effects.

READ: Avacta says partner Moderna takes collaboration to next level

The third and final phase of trials is pencilled in for July, followed by biologic licence application to the US Food and Drug Administration if successful.

“We are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from SARS-CoV-2,” said chief executive Stéphane Bancel.

Shares climbed 30% to US$86.79 at the opening bell on Monday.

Quick facts: Moderna Therapeutics Inc

Price: 152.52 USD

NASDAQ:MRNA
Market: NASDAQ
Market Cap: $60.35 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Benchmark Holdings' present at the Proactive One2One Virtual Forum

Benchmark Holdings' (LON:BMK) Trond Williksen, CEO & Septime Maguire, CFO pitch to investors at the Proactive One2One virtual forum.  Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability. We bring together biology and technology, to...

9 hours, 39 minutes ago

2 min read